BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rhea-AI Summary
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced two poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 22–26, 2025 in Boston.
Two abstracts: BBO-11818, an oral non-covalent pan-KRAS(ON)/(OFF) inhibitor showing robust anti-tumor activity in KRAS-mutant preclinical models, will be presented in Poster Session A on Oct 23, 12:30–4:00 PM ET by Carlos Stahlhut, PhD. BBO-10203, a first-in-class oral breaker of the RAS:PI3Kα interaction that inhibited tumor growth without inducing hyperglycemia in KRAS mutant models, will be presented in Poster Session C on Oct 25, 12:30–4:00 PM ET by Kerstin Sinkevicius, PhD. Abstracts are available on the AACR website.
Positive
- None.
Negative
- None.
News Market Reaction – BBOT
On the day this news was published, BBOT declined 4.19%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $38M from the company's valuation, bringing the market cap to $871M at that time.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 22-26, 2025, in Boston, Massachusetts. The abstracts released today can be found on the AACR website here.
Details on the abstracts are as follows:
- Title: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
- Session: Poster Session A
- Session Date/Time: Thursday, October 23, from 12:30 p.m. – 4:00 p.m. ET
- Presenter: Carlos Stahlhut, PhD, Associate Director, BBOT
- Title: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia
- Session: Poster Session C
- Session Date/Time: Saturday, October 25, from 12:30 p.m. – 4:00 p.m. ET
- Presenter: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
When will BBOT present BBO-11818 at the 2025 AACR-NCI-EORTC conference?
What is BBO-11818 and which BBOT presenter will discuss it (BBOT)?
When and where will BBOT present BBO-10203 at the AACR-NCI-EORTC 2025 conference?
What is the reported preclinical finding for BBOT's BBO-10203 (BBOT)?
How can investors view BBOT's abstracts from the AACR-NCI-EORTC conference?
What conference and dates cover BBOT's poster presentations (BBOT)?
